- Home
- FBRT vs EVMN Comparison
FBRT vs EVMN Comparison
Compare FBRT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | EVMN |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 892.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBRT | EVMN |
|---|---|---|
| Price | $8.58 | $23.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $13.50 | ★ $43.29 |
| AVG Volume (30 Days) | ★ 1.2M | 263.7K |
| Earning Date | 04-27-2026 | 03-05-2026 |
| Dividend Yield | ★ 16.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.40 | $13.89 |
| 52 Week High | $13.15 | $33.20 |
Technical Indicators
Market Signals| Indicator | FBRT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 49.89 |
| Support Level | $8.42 | $21.40 |
| Resistance Level | $9.23 | $25.50 |
| Average True Range (ATR) | 0.24 | 2.05 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 12.23 | 57.55 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.